Brands

Primary Cells

T5555 Normal Human Primary Intrahepatic Biliary Epithelial Cells (Cholangiocytes)

T5555 Normal Human Primary Intrahepatic Biliary Epithelial Cells (Cholangiocytes) by ABM — normal bile duct cholangiocytes; 5×10⁵ cells/1.0 ml, BSL-II. Seeding 5,000 cells/cm²; 300×g centrifuge on thaw; undisturbed 12h; media at 24h then every other day. TM087 Cholangiocyte Medium + G999 ECM flasks required. MTA required.

T5558 Normal Human Primary Sinusoidal Endothelial Cells

T5558 Normal Human Primary Sinusoidal Endothelial Cells by ABM — normal liver sinusoidal endothelium, endothelial-like, 5×10⁵ cells/1.0 ml, BSL-II. Sinusoidal Endothelial Cell Growth Medium (TM086) required; G299/G422 flasks. For liver LSEC biology and NASH research. MTA required.

T5995 Normal Human Primary Sinusoidal Endothelial Cells

T5996 Enhanced Primary Human Hepatocytes - 5 million

T5996 Enhanced Primary Human Hepatocytes by ABM — expanded primary hepatocytes retaining CYP activity; 5×10⁶ cells/1.0 ml, BSL-II. Seeding 10,000 cells/cm²; 90×g only centrifuge; max 18-day culture; media every 2–3 days. Hepatocyte Thawing Medium (TM102) + Growth Kit (TM103) required. MTA required.

T5997 Enhanced Primary Human Liver Sinusoidal Endothelial Cells

T5997 Enhanced Primary Human Liver Sinusoidal Endothelial Cells by ABM — expanded LSECs; MMR+/CD31+; 5×10⁵ cells/1.0 ml, BSL-II. Seeding 10,000 cells/cm²; max 1–2 passages; subculture at 70–80%. TrypLE Express (PBS wash first); 280×g; TM111 thaw → TM112 growth media; G422 coating. MTA required.

<h2>What Are RNA-Modifying Enzymes?</h2>
&nbsp;
RNA-modifying enzymes act on RNA substrates to add, remove, or chemically alter nucleotides and terminal structures. Key enzymes in this category include poly(A) polymerase (PAP), which adds untemplated adenosine residues to RNA 3' ends; T4 RNA Ligase 1, which joins single-stranded RNA; T4 RNA Ligase 2, which joins nicked duplex RNA; vaccinia virus capping enzyme (VCE), which adds a 7-methylguanosine cap to the 5' end of mRNA; 2'-O-methyltransferase, which modifies the cap to generate a Cap 1 structure; and RNA methyltransferases such as METTL3/METTL14 complex used in m6A epitranscriptomics research. These enzymes are foundational tools in the fast-growing field of mRNA-based therapeutics and diagnostics, as well as long-read sequencing library construction. Select RNA-modifying enzymes based on RNA substrate type (single-stranded, duplex, capped), required end structure, and downstream application (therapeutic vs. research grade).
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" aria-level="1">
T7 RNA Polymerase: The rapid powerhouse of in vitro transcription, ideal for producing large quantities of RNA from DNA templates for probes or functional mRNA research.
</li>
<li dir="ltr" aria-level="1">
Poly(A) Polymerase (Yeast &amp; E. coli): The definitive stabilizing agent, attaching adenosine tails to the 3' terminus of transcripts to enhance their longevity and translation efficacy&mdash;a crucial element for precise library preparation.
</li>
</ul>
&nbsp;
<h2>How to Choose RNA-Modifying Enzymes</h2>
&nbsp;
Poly(A) tailing vs. RNA ligation.
Poly(A) polymerase is used when a 3'-poly(A) tail is needed for mRNA stabilization, translation enhancement, or as a primer binding site for oligo(dT)-based cDNA synthesis. T4 RNA Ligase 1 (single-strand-specific) is used for adaptor ligation to RNA 3' ends in small RNA sequencing library preparation. T4 RNA Ligase 2 truncated version (paired with a splint oligonucleotide) gives higher efficiency adaptor ligation with less secondary structure bias.
mRNA capping
5'-cap structures protect mRNA from exonucleolytic degradation and are recognized by eIF4E for ribosome recruitment. Vaccinia Capping Enzyme adds a Cap 0 structure; co-treatment with 2'-O-methyltransferase (mRNA Cap 2'-O-Methyltransferase) converts Cap 0 to Cap 1, which reduces innate immune recognition -- critical for therapeutic mRNA applications. Co-transcriptional capping with CleanCap analogs avoids the separate capping step.
Epitranscriptomics
m6A RNA methyltransferases (METTL3, METTL14, WTAP complex) and demethylases (FTO, ALKBH5) are used to add or remove N6-methyladenosine modifications in cellular RNA for functional studies. These enzymes require S-adenosylmethionine (SAM) as a methyl donor and are supplied at a microgram scale for biochemical assays.
RNase inhibitor pairing
All RNA-modifying enzyme reactions require an RNase-free environment. Include RNase inhibitor protein at 0.5-2 U per microliter in reactions without heat-inactivation capability. Use DEPC-treated water and certified RNase-free tubes and tips for all RNA work.
Application scale
Research-grade RNA-modifying enzymes are available in standard unit sizes for individual experiments. For manufacturing-adjacent workflows (large-scale IVT for mRNA vaccines or CAR-T cell therapy applications), contact MBP for volume pricing and GMP-compatible sourcing options.
&nbsp;
<h2>Specifications Context</h2>
&nbsp;
Poly(A) polymerase activity is measured as the amount of enzyme incorporating 1 nmol of AMP into acid-precipitable RNA in 30 minutes at 37 degrees C. Typical poly(A) tail lengths of 100-250 nucleotides are generated in 10-20 minute reactions at 37 degrees C with 1 mM ATP and 2-5 U of enzyme per microgram of RNA. Vaccinia Capping Enzyme reaction efficiency exceeds 95% for IVT transcripts of 500-5000 nt when used at recommended ratios; verify by LC-MS or HPLC analysis for therapeutic applications. Co-transcriptional Cap 1 capping using modified trinucleotide cap analogs is increasingly adopted in mRNA manufacturing to eliminate separate enzymatic capping steps.&nbsp;
&nbsp;
Prepared to customize your transcripts? <a href="https://mbpinc.net/contact-us">Contact the MBP team</a> today for a personalized quote on our RNA-modifying tools.

RNA-modifying enzymes

MSDS

T7 RNA Polymerase

Unit Quantity

Concentration

Components

Storage Buffer

Storage Condition

Note

Shipping Condition

Tumor cells

Thawing Protocol

Cell Line Catalog (Volume 2)

T8000 EACH-1 Cells

EACH-1 Cells (T8000) by MBP are novel extra-axial chordoma tumor cells, tumorigenic and able to form colonies on soft agar. Used for research on the rare low-grade malignant tumor parachordoma. Human (H. sapiens), bone tissue, adherent polygonal. BSL II. 1&times;106 cells / 1.0 mL, frozen. MTA required.

T8001 IU-TAB-1 Cells

T8001 IU-TAB-1 Cells by MBP. 1&times;106 cells / 1.0 mL, frozen. Contact MBP for full specifications and pricing.

T8008 CUTLL1 Cells

CUTLL1 Cells (T8008) by MBP are derived from T-cell lymphoblastic leukemia (T-ALL) expressing high NOTCH1 levels, with t(7;9)(q34;q34) translocation. A valuable model for cancer research and NOTCH1 signaling studies. Human (H. sapiens), blood, suspension growth. BSL II. 1&times;106 cells / 1.0 mL, frozen. MTA required.

T8009 ASAN-PaCa Cells

ASAN-PaCa Cells (T8009) by MBP are a pancreatic cancer cell model with high proliferation capacity and CK19 expression. Note: Depositor has confirmed possible cross-contamination with T3M-4 cells — verify cell identity before use. Human (H. sapiens), adherent polygonal. BSL II. 1&times;106 cells / 1.0 mL, frozen. MTA required.

T8020 SUNE2 Cells

T8020 SUNE2 Cells are a human nasopharyngeal carcinoma (NPC) cell line with low EBV DNA and faster proliferation than other NPC lines, derived from a Stage III undifferentiated squamous cell carcinoma. Supplied by ABM as 1&times;106 cells/1.0 ml, frozen; BSL-2; RUO. MTA required.

T8021 SEM-1 Cells

SEM-1 Cells (T8021) by MBP are derived from mediastinal seminoma and express SALL-4, AP-2&gamma;, CAM5.2, and stem cell markers (OCT3/4, NANOG, c-KIT, SOX17, SOX2). Hypotriploid chromosome number. Model for extragonadal germ cell tumor research. Human (H. sapiens), adherent round. BSL II. 1&times;106 cells / 1.0 mL, frozen. MTA required.